Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

计划入组 189 人 · 首次发布于 2006 年 5 月 16 日

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

计划入组 20 人 · 首次发布于 2022 年 8 月 22 日

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

计划入组 61 人 · 首次发布于 2019 年 8 月 14 日

SYK-623

MT-SYK-03

SYK inhibitors (Origenis)

Sørlandet Sykehus HF

Norway

Sykehuset Innlandet Hf

Norway

Sykehuset Telemark Hf

Norway

Hutchison MediPharma's Sovleplenib Demonstrates Efficacy in Autoimmune Disorders

Sanofi Licenses Dual JAK/SYK Inhibitor Gusacitinib from Formation Bio in €545 Million Deal

HUTCHMED's Sovleplenib Receives Priority Review and Breakthrough Designation in China for Rare Blood Disorder